Figure 7.

The normalized a-wave (A,C,E,G) and b-wave (B,D,F,H) amplitudes are plotted versus the light intensity for all the treatment groups in C57BL/6J mice (n = 4 per group). The amplitudes are shown ± the standard deviations. No significant differences can be observed at day 1 (baseline) between all the treatment groups. The treatment effects started to show from seven-days post-injection onwards. A slight effect was observed for the 20 mg/kg treatment group for both the a- and b-wave. The 30 and 40 mg/kg caused similar and moderate effects, and 50 and 70 mg/kg caused more extreme decreased amplitudes. From day 19 onwards, more long-term effects were visible. No significant differences were observed between the control, 10 mg/kg and 20 mg/kg groups. A significant and moderate effect was observed for the 30 mg/kg treatment group. Injection of 30 mg/kg SI caused a reduction of the a- and b-wave amplitudes of roughly 50% at least up to two-months post-injection. More extreme effects were observed for the higher doses (40, 50 and 70 mg/kg). Reduced responses to 20% to non-recordable ERG responses were observed in these groups. ns: not significant, **: p ≤ 0.01, ***: p ≤ 0.001, and ****: p ≤ 0.0001.